(PSYCHIATRIC TIMES) - NEW YORK, Jan. 18 -- Gauging the winds of medical advances is an iffy proposition at best, but for psychiatrists the new year is likely to bring much-anticipated data on the safety and efficacy of antipsychotic and bipolar medications in children and adolescents.
With pediatric safety and efficacy data lacking for most drugs used to treat schizophrenia and bipolar disorder, use of these drugs in pediatric patients is more off-label than on-label, noted Christoph U. Correll, of the Albert Einstein College of Medicine in the Bronx. Dr. Correll is also a member of the American Academy of Child and Adolescent Psychiatry (AACAP).
But an ongoing initiative on the part of industry, academia, and the NIH to change the situation should bear fruit in 2007, Dr. Correll said, just as it did in 2006 with the announcement of a new indication for treating irritability in childhood autism for Risperdal (risperidone).
For full article, please visit: